Qnovia is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. The company's drug delivery platform, the RespiRx™, is the first orientation-agnostic, portable vibrating mesh nebulizer that effectively operates in any position held by the patient. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs. The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/10/24 | $16,000,000 | Series B |
Blue Ledge Capital Evolution VC Partners Gaingels Vice Ventures | undisclosed |
